Compare IDN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDN | BOLD |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 60.8M |
| IPO Year | 2014 | 2024 |
| Metric | IDN | BOLD |
|---|---|---|
| Price | $2.41 | $2.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $7.33 | $4.00 |
| AVG Volume (30 Days) | ★ 297.2K | 107.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 32.47 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $40.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.32 | $0.96 |
| 52 Week High | $9.08 | $3.16 |
| Indicator | IDN | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 31.57 | 39.30 |
| Support Level | N/A | $2.39 |
| Resistance Level | $3.00 | $2.79 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 18.02 | 18.57 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.